These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16169728)

  • 41. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.
    Pritchard KI; Goss PE; Shepherd L
    Breast; 2006 Feb; 15 Suppl 1():S14-20. PubMed ID: 16500236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant endocrine therapy in breast cancer.
    Beresford MJ; Ravichandran D; Makris A
    Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
    Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
    Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prescribing extended adjuvant letrozole.
    Gelmon K
    Breast; 2007 Oct; 16(5):446-55. PubMed ID: 17544670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK; Ryan A
    Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
    Nagykálnai T
    Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
    Sulkes A
    Isr Med Assoc J; 2005 Apr; 7(4):257-61. PubMed ID: 15847208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant endocrine therapy for early breast cancer: the story so far.
    Gradishar WJ
    Cancer Invest; 2010 May; 28(4):433-42. PubMed ID: 20307199
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
    Okubo I; Kondo M; Toi M; Ochiai T; Miki S
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):351-63. PubMed ID: 15791818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on adjuvant hormonal treatment of early breast cancer.
    Lao Romera J; Puertolas Hernández TJ; Peláez Fernández I; Sampedro Gimeno T; Fernández Martínez R; Fernández Pérez I; Iranzo González Cruz V; Illarramendi Mañas JJ; Garcerá Juan S; Ciruelos Gil EM
    Adv Ther; 2011 Sep; 28 Suppl 6():1-18. PubMed ID: 21922392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
    Bender CM; Sereika SM; Brufsky AM; Ryan CM; Vogel VG; Rastogi P; Cohen SM; Casillo FE; Berga SL
    Menopause; 2007; 14(6):995-8. PubMed ID: 17898668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A practical overview of aromatase inhibitors.
    Younus J; Vandenberg TA
    Anticancer Res; 2005; 25(3c):2497-502. PubMed ID: 16080483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
    Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
    Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.